Pazopanib 13CD3

Pazopanib 13CD3 is a drug that is used in the treatment of advanced renal cell carcinoma, soft tissue sarcoma and non-small cell lung cancer. It is a tyrosine kinase inhibitor that works by blocking the action of enzymes that promote the growth of cancer cells. The drug is administered orally in the form of tablets. The chemical structure of Pazopanib 13CD3 is similar to that of Pazopanib, but it contains deuterium atoms. Deuterium is a stable isotope of hydrogen that can replace hydrogen atoms in molecules. The incorporation of deuterium atoms in Pazopanib 13CD3 increases the drug's half-life and reduces the clearance rate from the body. This leads to a longer duration of action and better efficacy. The recommended dosage of Pazopanib 13CD3 varies depending on the type of cancer being treated and the patient's medical history. Patients are advised to take the drug at the same time each day with or without food. The drug can cause side effects such as fatigue, nausea, diarrhea, hypertension, and liver toxicity. Patients should inform their doctor if they experience any adverse effects. In conclusion, Pazopanib 13CD3 is a potent tyrosine kinase inhibitor that is effective in the treatment of advanced renal cell carcinoma, soft tissue sarcoma and non-small cell lung cancer. The incorporation of deuterium atoms in the drug's chemical structure provides improved pharmacokinetic properties and better efficacy. Patients should follow their doctor's instructions carefully and report any adverse effects.